Bausch + Lomb Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas J. Appio
- Full Time Employees
- 13,000
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 520 Applewood Crescent Vaughan ON Canada L4K 4B4
- IPO Date
- May 6, 2022
- CIK
- 0001860742
- Website
- bausch.com
- Similar Companies
- Business
- Bausch + Lomb Corporation functions as a global leader in eye health, committed to enhancing and preserving vision. Its operations are structured across three distinct divisions: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health segment delivers an extensive portfolio of contact lenses, encompassing both daily disposable and planned replacement modalities, alongside essential lens care solutions. This division also provides a variety of over-the-counter eye drops, vitamins, and mineral supplements designed to address common conditions such as dry eye, allergies, and redness, including brands like Lumify and the recently acquired Blink portfolio. The Ophthalmic Pharmaceuticals division offers both branded and generic prescription medications for post-operative management and the treatment of numerous ocular conditions, including glaucoma, ocular hypertension, retinal disorders, and eye inflammation, further strengthened by the recent acquisition of Xiidra for dry eye. The Surgical division equips eye care professionals with advanced instruments and technologies for interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include sophisticated intraocular lenses and their delivery systems, phacoemulsification devices, and a comprehensive range of surgical tools, such as the enVista Envy IOL and Storz Ophthalmic Instruments. Established in 1853, the company maintains its corporate headquarters in Vaughan, Canada.
Company News
Bausch + Lomb: Profits Return In Q3 As A Recovery Story, While Pipeline Grows
Are You Looking for a Top Momentum Pick? Why Bausch + Lomb (BLCO) is a Great Choice
Midterm Election Rally: 5 Relative Price Strength Stocks to Buy
Best Growth Stocks to Buy for November 5th
Bausch + Lomb: 3 Key Takeaways for Long-Term Investors
Why Bausch + Lomb (BLCO) Might be Well Poised for a Surge
Why Bausch + Lomb (BLCO) is a Top Momentum Stock for the Long-Term
BLCO vs. HQY: Which Stock Is the Better Value Option?
Best Momentum Stock to Buy for November 2nd
Why Bausch + Lomb (BLCO) is a Top Value Stock for the Long-Term
New Strong Buy Stocks for November 2nd
Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Education
What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call
Bausch + Lomb Corporation (BLCO) Q3 2026 Earnings Call Transcript
Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates
Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance
Bausch + Lomb (NYSE:BLCO) Shares Down 5.8% – What’s Next?
Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance
Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting
Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28